tirzepatide and cardiovascular outcomes of semaglutide for patients with type 2 diabetes in clinical practice In patients with type 2

The FDA approved a GLP-1 pill from Eli Lilly called Foundayo

PlexusDx has no affiliation with either brand

If your GLP-1 medication has stopped producing weight loss results, you may be experiencing treatment resistancea common challenge affecting patients on Ozempic and similar drugs

Conclusion When adjusted for differences in sex, age, and body weight, semaglutide exposure was similar between subjects with RI and subjects with normal renal function

GLP-1 Receptor Agonists and the Eye: Evidence, Mechanisms, and Clinical Guidance A new multidisciplinary expert consensus published in Diabetes, Obesity & Metabolism (2025) brings clarity to a question often raised in clinical practice: Do GLP-1 receptor agonists increase the risk of ocular complications such as diabetic retinopathy or optic neuropathy